

Saturday, October 24, 4:30–6:00 p.m. MT

Oral Abstract Session

Late-Breaking Research Orals: Pediatrics, Genetics, and Glomerular Diseases

Four Seasons Ballroom 2

Moderators: Vandana Dua Niyar, MD, FASN; Meghan E. Sise, MD, MS

Note: Full abstracts will be posted on the ASN website on the day of presentation, and on the JASN website on November 10.

-
- 4:30 PM **SA-OR073 Efficacy and Safety of Obinutuzumab in Adolescents with Active Lupus Nephritis: Primary Results from POSTERITY, a Phase II Global Trial** – Marina Vivarelli, Deborah Levy, Gabriel Vega Cornejo, Maria T. Terreri, Aleksandra Zurowska, Adolfin E. Zuta, Joan Calzada-Hernández, Julien Hogan, Sandra Enciso-Peláez, Agustín Remesal, Louise Oni, Peiqing Yu, Felix Erblang, Olga Mitrofanova, William F. Pendergraft, Patricia B. Lehané
- 4:42 PM **SA-OR074 Empagliflozin Therapy in Patients with Autosomal Dominant Polycystic Kidney Disease: A Feasibility Randomized Controlled Trial** – Stephen L. Seliger, Berenice Y. Gitomer, Zhiying You, Wei Wang, Anna Ostrow, Emily Andrews, Charalett E. Diggs, Diana George, Miranda West, Kristen L. Nowak, Terry J. Watnick, Michel Chonchol
- 4:54 PM **SA-OR075 SGLT2 Inhibitors in Alport Syndrome: A National Multicenter Study (GLIFAS)** – Domenico Santoro, GLIFAS Group
- 5:06 PM **SA-OR076 Povecacept for Treatment of IgA Nephropathy: RAINIER Phase 3 Interim Efficacy and Safety Analysis (IA)** – Richard A. Lafayette, Hong Zhang, Seung Hyeok Han, Yusuke Suzuki, James A. Tumlin, Bobby Chacko, Irene L. Noronha, Arvind Madan, Raphael Duivenvoorden, Jamil R. Azzi, Carla M. Nester, Cassie Dong, Neil Ahluwalia, Jiahua Li, Carmen Bozic, Ogo I. Egbuna, Muh Geot Wong, Jonathan Barratt
- 5:18 PM **SA-OR077 Randomized Controlled Phase 2 Study to Evaluate Iptacopan in Participants with Active ANCA-Associated Vasculitis (AAV): Interim Renal-Focused Results** – Grégory Pugnet, Benjamin Terrier, Christian Löffler, Zhanzheng Zhao, Sebastian J. Magri, Jorge A. Brigante, Fatma Alibaz-Oner, Rachel B. Jones, Min Chen, Rodolfo N. Alvarado, Adrian Schreiber, Anna Bazsó, Albrecht Bettrains, Shilpa Muthusamy, Malika Hanser, Julia Wagner, Swati Ghanshani, Prasanna Kumar Nidamarthy, Imelda Schuhmann, Guido Junge
- 5:30 PM **SA-OR078 Sustained Efficacy and Safety in C3 Glomerulopathy Following 36 Months of Oral Treatment with Iptacopan: Interim Participant Results from the APPEAR-C3G Extension Study** – Carla M. Nester, Richard J. Smith, David Kavanagh, Marina Vivarelli, Giuseppe Remuzzi, Minghui Zhao, Edwin K. Wong, Shiwei Cao, Rubeen K. Israni, Raquel Luna Yolba, Severina Jacinto-Sanders, Jean Grisouard, Andrew S. Bomback
- 5:42 PM **SA-OR079 Interim Results from the Adult IgAN and Primary Membranous Nephropathy (pMN) Cohorts in the Atacicept PIONEER Trial** – Richard A. Lafayette, Jonathan Barratt, Chris Mix, Dana V. Rizk, Brad Rovin, Pamela D. Winterberg, Tao Sheng, James A. Tumlin, Glenn M. Chertow, Christoph Wanner
- 6:00 p.m. Adjourn